Nyxoah SA

What they do

Nyxoah SA is a Belgium-based surgical and medical instrument company focused on a neurostimulation device for obstructive sleep apnea. Its Genio system is a leadless, battery-free hypoglossal nerve stimulator that is implanted under the chin and controlled by a wearable activation chip. The company is conducting clinical trials and regulatory activities to support commercialization.

Revenue drivers

• Sleep Apnea Device — The primary product line, the Genio system, is pre-commercial or early commercial with no significant revenue reported for 2024 or 2025 from this segment.
• First Articles — Relates to initial manufacturing runs; no material revenue is reported to date.
• Clinical Trials — No revenue generated; costs associated with trials are investments in regulatory approval.
• Activation Chip Improvements — Development activities for enhancing the external activation chip, not a revenue source.

Recent performance

No specific financial results for 2025 are included in the provided excerpts. The filing data indicates no revenue for the Sleep Apnea Device segment in 2024 or 2025. As a pre-commercial company, Nyxoah continues to invest in clinical trials, first articles, and activation chip improvements. The company reported a net loss, consistent with its development stage.

Strategy

Nyxoah's strategy centers on obtaining regulatory approval and commercializing the Genio system for obstructive sleep apnea. Key investments include clinical trials, manufacturing scale-up for first articles, and enhancements to the activation chip. The company has pursued financings, including a registered direct offering in July 2024 and a convertible bond issuance in November 2025, to fund these activities. Management priorities appear focused on regulatory milestones and market access.

Risks

• Regulatory Approval Risk — The Genio system requires regulatory clearances, and failure or delay could prevent commercialization.
• Pre-commercial Stage — The company has no significant revenue and relies on external financing to fund operations.
• Clinical Trial Risk — Ongoing and future trials may not achieve favorable results, delaying approval.
• Competition — Larger, established competitors in sleep apnea treatment may impede market adoption.

Outlook

Management has not provided specific revenue guidance. The company continues to focus on regulatory submissions and clinical development for the Genio system. Future prospects depend on successful pivotal trial outcomes and approval. Cash burn is expected to continue as commercialization efforts ramp up.